Evidence map›Paper›PMID 40401975›Full record

ArticleMicrobiology spectrum2025

Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study.

Mona Mustafa Hellou, Abinash Virk, Angel P Strasburg, William S Harmsen, Paschalis Vergidis, Kirstin Kooda, Kami D Kies, Alexander D Donadio, Jay Mandrekar, Audrey N Schuetz and 1 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Assessment of Clinical Significance of MolecularOpen forum infectious diseases · 2026
    Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mona Mustafa HellouDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5222-1786
Abinash VirkDivision of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Angel P StrasburgDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
William S HarmsenDepartment of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Paschalis VergidisDivision of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6581-3956
Kirstin KoodaDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
Kami D KiesDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Alexander D DonadioDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Jay MandrekarDepartment of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Audrey N SchuetzDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5837-270X
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumonia may be caused by a diverse group of microorganisms; however, a microbiologic diagnosis is not universally made. Molecular tests such as the BIOFIRE FILMARRAY Pneumonia Panel (BF-PP) offer the possibility of rapid identification of potential pneumonia pathogens. This retrospective analysis was conducted as a sub-study of a recently published randomized controlled trial. Specimens from patients with suspected pneumonia were tested by the BF-PP, with results compared to cultures. The overall BF-PP positivity rate was 44.8% (252/563), and was higher [64.6% (164/254)] in specimens from patients ultimately diagnosed with pneumonia. Discrepancies between the BF-PP and cultures were most common for

Indexed as

BacteriaMolecular Diagnostic TechniquesPneumoniaPneumonia, BacterialAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMoraxella catarrhalisRetrospective StudiesSensitivity and SpecificityStreptococcus pneumoniaeanalytical performanceBIOFIREconcordancenegative percent agreementpneumoniapositive percent agreement

Identifiers

PMID40401975
PMCPMC12210945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.